Recently, immune checkpoint blockade (ICB) therapy, which targets the dysfunctional immune system and induces cancer-cell killing by CD8-positive T cells, has been reported not only to revolutionize the field of cancer treatment but has also establish itself as a crucial immunotherapy option for combating cancer (Abril-Rodriguez and Ribas, 2017). This evidence concerns the gene CD8A and cancer.